{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:07:45Z","timestamp":1774804065852,"version":"3.50.1"},"reference-count":49,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"This work was partially supported by National Institute of Health","award":["1R56HD106612-01"],"award-info":[{"award-number":["1R56HD106612-01"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.1080\/17425247.2023.2169272","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T02:08:06Z","timestamp":1673662086000},"page":"301-311","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity"],"prefix":"10.1080","volume":"20","author":[{"given":"Ziyaur","family":"Rahman","sequence":"first","affiliation":[{"name":"Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahir","family":"Khuroo","sequence":"additional","affiliation":[{"name":"Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman M","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathish","family":"Dharani","sequence":"additional","affiliation":[{"name":"Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canberk","family":"Kayalar","sequence":"additional","affiliation":[{"name":"Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew A.","family":"Kuttolamadom","sequence":"additional","affiliation":[{"name":"Department of Engineering Technology & Industrial Distribution, College of Engineering, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamba Omar","family":"Sangar\u00e9","sequence":"additional","affiliation":[{"name":"Department of Biology, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor A.","family":"Khan","sequence":"additional","affiliation":[{"name":"Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1086\/504873"},{"issue":"1","key":"cit0002","first-page":"1","volume":"8","author":"Zheng W","year":"2013","journal-title":"Iran J Parasitol"},{"key":"cit0003","unstructured":"Daraprim\u00ae FDA label. Accessed on August 08, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/008578s019lbl.pdf."},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-4-521"},{"key":"cit0005","unstructured":"Fansidar\u00ae FDA label. Accessed on August 08, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/18557slr015_fansidar_lbl.pdf."},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91873-6"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp372"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3390\/jof4040127"},{"key":"cit0009","unstructured":"CDC. Toxoplasmosis: epidemiology & risk factors, CDC. Available from: https:\/\/www.cdc.gov\/parasites\/toxoplasmosis\/epi.html#:~:text=Toxoplasmosis%20is%20caused%20by%20the,have%20been%20infected%20with%20Toxoplasma"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.22-0099"},{"key":"cit0011","volume-title":"Congenital toxoplasmosis, in StatPearls","author":"Kota AS","year":"2022"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2021.1967628"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406303302604"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac645"},{"key":"cit0015","unstructured":"CDC. Parasites - Toxoplasmosis (Toxoplasma infection): treatment. August 28, 2022]; Available from: https:\/\/www.cdc.gov\/parasites\/toxoplasmosis\/treatment.html#:~:text=Most%20healthy%20people%20recover%20from,and%20sulfadiazine%2C%20plus%20folinic%20acid"},{"key":"cit0016","unstructured":"MayoClinic. Toxoplasmosis. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/toxoplasmosis\/diagnosis-treatment\/drc-20356255."},{"issue":"8","key":"cit0017","first-page":"1","volume":"51","author":"Kaplan JE","year":"2002","journal-title":"MMWR Recomm Rep"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199909100-00007"},{"key":"cit0019","unstructured":"Drugs@FDA. Accessed on August 08, 2022. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"cit0020","unstructured":"Drugs.com. Pyrimethamine dosage. August, 2022; Available from: https:\/\/www.drugs.com\/dosage\/pyrimethamine.html."},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000437856.09540.11"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.08.064"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9511-5"},{"key":"cit0024","unstructured":"FDA, Bulk drug substances used in compounding under section 503A of the FD&C Act. 2020. Accessed on Sept 26, 2022. https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/bulk-drug-substances-used-compounding-under-section-503a-fdc-act."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv177"},{"key":"cit0026","unstructured":"Drugs.com. Daraprim prices, coupons and patient assistance programs. August 29, 2022]; Available from: https:\/\/www.drugs.com\/price-guide\/daraprim."},{"key":"cit0027","unstructured":"Drugs.com. Pyrimethamine prices, coupons and patient assistance programs. August 28, 2022]; Available from: https:\/\/www.drugs.com\/price-guide\/pyrimethamine."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-013-0005-9"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1177\/875512259200800408"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2020.1764027"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00306"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0225-6"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118651"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120059"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01775-0"},{"key":"cit0036","unstructured":"USP43-NF38, Pyrimethamine Tablets monograph. 2022. p. 3787."},{"key":"cit0037","unstructured":"FDA, guidance for orally disintegrating tablets. 2008."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2013.06.006"},{"issue":"8","key":"cit0039","first-page":"1651","volume":"8","author":"Onyeji CO,OSI","year":"2009","journal-title":"Afr J Biotechnol"},{"key":"cit0040","volume-title":"The merck index: an encyclopedia of chemicals, drugs, and biologicals","author":"Buntrock RE","year":"2006"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1021\/bp00014a008"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/0032-3861(76)90221-4"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.14227\/DT190112P59"},{"key":"cit0044","unstructured":"WHO, Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. WHO Technical Report Series No. 2006;937, (937)."},{"key":"cit0045","unstructured":"FDA, guidance for industry \u2013 M9 biopharmaceutics classification system based biowaivers. 2021."},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-005-1665-4"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/BF03191170"},{"key":"cit0048","unstructured":"FDA, guidance for industry - bioavailability and bioequivalence studies submitted in NDAs or INDs \u2014 general considerations. 2014."},{"key":"cit0049","unstructured":"FDA, Distributed manufacturing and point-of-care manufacturing of drugs, 2022."}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2023.2169272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:31:11Z","timestamp":1675841471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2023.2169272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,29]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1080\/17425247.2023.2169272"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2023.2169272","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}